À PROPOS DE CET ÉPISODE
Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Signup now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/rp9e1V8dfPk.
We revisit gene editing stocks once per year because things move very slowly in this space. While there may be upwards of 27 gene editing stocks out there, our focus is on the three biggest – Beam Therapeutics BEAM, Intellia Therapeutics NTLA, and CRISPR Therapeutics CRSP. Each of these companies is racing to bring treatments to market using their respective gene editing technologies. Of these three gene editing companies, CRISPR seems to be the furthest ahead as they await regulatory approval - in the USA and UK/Europe - for the first gene editing enabled therapy, exa-cel. These updates on gene editing stocks provide investors with the latest news on the biggest players.
